Now live: Pro — the full 13F research suite for serious investorsSee pricing →
Sarissa Capital Management LP

Q3 2023 · 13F-HR

Sarissa Capital Management LPholdings as filed

Filed 2023-11-14 · accession 0000899140-23-001108

$742.4M
Reported value
11
Positions
2023-09-30
Period end
View analyzed profile →PRO

Holdings as filed

CUSIPTickerIssuerValue% port.SharesClassVoting
G01767105ALKSALKERMES PLC$197.3M26.6%7,042,200CommonSOLE
09062X103BIIBBIOGEN INC$165.3M22.3%643,000CommonSOLE
46333X108IRWDIRONWOOD PHARMACEUTICALS INC$157.8M21.3%16,390,000CommonSOLE
45781M101INVAINNOVIVA INC$94.5M12.7%7,277,000CommonSOLE
375558103GILDGILEAD SCIENCES INC$69.0M9.29%920,400CommonSOLE
64125C109NBIXNEUROCRINE BIOSCIENCES INC$41.2M5.55%366,000CommonSOLE
023111206AMARIN CORP PLC$9.6M1.29%10,442,453CommonSOLE
09058V103BCRXBIOCRYST PHARMACEUTICALS INC$5.5M0.74%775,000CommonSOLE
929033108VOR BIOPHARMA INC$1.3M0.18%618,000CommonSOLE
59045L106MERSANA THERAPEUTICS INC$698,5000.09%550,000CommonSOLE
75915K309RGLSREGULUS THERAPEUTICS INC$253,7010.03%185,183CommonSOLE

Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.